CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Lymphoma
LYMPHOMA ADVISOR
FEATURED CONTENT
-
-
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy. -
Mass Cytometry for Profiling the Classic Hodgkin Lymphoma Microenvironment
The technique allows researchers to detect various subpopulations of immune cells by simultaneous interrogation of dozens of proteins. -
Autoimmune Conditions and Primary CNS Lymphoma Risk
Primary central nervous system lymphoma (PCNSL) is a rare (incidence rate of 0.6 cases per 100,000 person years) non-Hodgkin lymphoma (NHL) found in the brain, spinal cord, and leptomeninges. -
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
VIDEO SERIES
LYMPHOMA NEWS
Long-Term Follow-Up of R-CHOP and Rituximab Maintenance in Elderly Patients With Mantle Cell Lymphoma
Study Finds Real-World Outcomes Differ for Idelalisib in FL and CLL
Liso-Cel Shows Durable Activity in Diffuse Large B-Cell Lymphoma
Older Patients With Follicular Lymphoma Benefit From Appropriate Therapy
High Use of Oncology Nurse Navigators Showed Similar Clinical Outcomes for White, Nonwhite Patients with DLBCL
Want to read more?
Please login or register first to view this content.
Next post in Lymphoma
